Latest insight from Medicines Law & Policy

The European Commission’s proposal for an EU wide compulsory licensing mechanism

In 2006 the European Generics Association was seeking clarification from the European Commission on whether generic versions of oseltamivir (Tamiflu) could be supplied to...

Updated TRIPS Flexibilities Database

In January 2023, a number of cystic-fibrosis patient organisations asked the governments of Brazil, India, South Africa and Ukraine to invoke compulsory licensing and...

New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments

A new briefing paper based on Medicines Law & Policy research outlines the legal instruments available for countries seeking to access key therapeutics to...

Protecting Public Health through Technology Transfer: The Unfulfilled Promise of the TRIPS Agreement

This article was previously published by the Health and Human Rights Journal. The scrambling for access to COVID-19 vaccines by developing countries has reignited the...

How not to solve a crisis: The European Commission’s Plan for Transferable Data Exclusivity...

Drug-resistant infections, sometimes called “superbugs,” killed an estimated 1.27 million people in 2019, a number set to rise to 50 million by 2050. It is...

Right to breathe takes precedence over company profits: Families of cystic fibrosis patients seek...

“Not even the doctors believed it would be so miraculous,” says 22-year old Rafaella Pereira. In two days, a new cystic fibrosis medicine took...

Never miss a post! Sign up for ML&P's mailing list by entering your information below. The list will only be used to inform you of new content (messages are sent approximately once a month).